Showing results (141-150 of 181) with videos related to

Sort By:
Pageof 19
Cancer Medicine|July 5, 2023
Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinomaKazuyuki Numakura, Yuya Sekine, Shingo Hatakeyama, et al.
Nihon Hinyokika Gakkai Zasshi. the Japanese Journal of Urology|March 7, 2012
[Primary retroperitoneal carcinoid tumor associated with multiple endcrine neoplasia (men) type 1: a case report]Syuji Chiba, Kazuyuki Numakura, Kiyofumi Satoyoshi, et al.
Urologic Oncology|June 15, 2026
Association of EVITA with safety in advanced urothelial carcinoma: A multicenter real-world studyKeita Ishimoto, Takuma Narita, Yuya Sekine, et al.
The Prostate|November 6, 2025
The Impact of Early Modification of Upfront Androgen Receptor Signaling Inhibitors on Survival Outcomes in Metastatic Hormone-Sensitive Prostate CancerShintaro Narita, Takafumi Yanagisawa, Shingo Hatakeyama, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|December 14, 2020
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective studyShingo Hatakeyama, Sei Naito, Kazuyuki Numakura, et al.
International Journal of Clinical Oncology|September 22, 2023
Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study GroupShigemitsu Horie, Sei Naito, Shingo Hatakeyama, et al.
European Urology Open Science|May 21, 2026
Real-world Outcomes of Adjuvant Nivolumab in High-risk Bladder and Upper Tract Urothelial Carcinoma after Radical SurgeryShunsuke Tazawa, Masanao Shinohara, Yohei Kawashima, et al.
International Journal of Clinical Oncology|January 1, 2022
Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective studyRenpei Kato, Sei Naito, Kazuyuki Numakura, et al.
Urologic Oncology|September 21, 2021
External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective studyKazutaka Okita, Shingo Hatakeyama, Sei Naito, et al.
Cancer Medicine|October 31, 2023
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group databaseTomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, et al.
Pageof 19